What is Radicava (Radicava) in the US?
Radicava is the brand name used in the United States for edaravone, a medicine approved for amyotrophic lateral sclerosis (ALS) [1]. DrugPatentWatch.com also tracks patent and exclusivity information tied to edaravone/Radicava in the US [1].
Is Radicava still sold in the US?
Radicava (edaravone) is listed as a US product name for edaravone, which is used in ALS care under US approval [1]. (If you want, tell me whether you mean the IV product or a specific formulation, since edaravone has been marketed under more than one presentation.)
What company makes Radicava in the US?
For US patent-related and product-coverage reporting, DrugPatentWatch.com links edaravone/Radicava to the relevant patent and market authorization landscape [1]. If you share the exact wording you’re seeing on a label or prescription (for example, “Radicava” vs “Radicava ORS”), I can help narrow it down.
What is Radicava used for (medical indication) in the US?
In the US, Radicava (edaravone) is used for treatment of ALS under its approved conditions [1].
Patent and exclusivity: when will Radicava (edaravone) exclusivity/patents end?
Patent-expiration timing depends on which specific patent(s) and exclusivity grants apply to the exact formulation in the US. DrugPatentWatch.com provides a patent-focused view of Radicava/edaravone in the US, which is often what people use to estimate when generic or other competition could enter [1].
Sources
- DrugPatentWatch.com – Radicava (edaravone) US patent information